• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Do Cervical Cancer Patients Treated with LEEP or Conization Have Higher Preterm Birth Rates?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Data on pregnancy outcomes among patients with early-stage cervical cancer who have undergone fertility-sparing surgery are limited
  • Nitecki et al. (Obstetrics & Gynecology, 2021) evaluated outcomes of the first pregnancy after fertility-sparing surgery in patients with early-stage cervical cancer

METHODS:

  • Population-based study
  • Population
    • 18 to 45 years
    • History of stage I cervical cancer who conceived at least 3 months after a fertility-sparing surgery
    • Acceptable surgeries
      • Cervical conization
      • Loop electrosurgical excision procedure
    • Excluded surgeries: Trachelectomies
  • Exposures
    • Case group: Patients with cervical cancer and fertility sparing surgery
    • Cancer control group: Patients with cervical cancer who delivered before their diagnosis
    • Population control group: Individuals without cancer
  • Study design
    • Propensity scores were used to match similar women from two groups in a 1:2 ratio of case group participants to control group participants
    • Logistic regressions were used to evaluate outcomes
  • Primary outcome
    • Preterm birth (<37 weeks)
  • Secondary outcomes
    • Growth restriction
    • Neonatal morbidity
    • Stillbirth
    • Cesarean delivery
    • Severe maternal morbidity

RESULTS:

  • Case patients: 107 | Population control patients: 214 | Cancer control patients: 173
    • Squamous cell carcinoma: 63.2%
    • Adenocarcinoma: 30.8%
  • Patients in the case group had higher odds of preterm birth (<37 weeks) vs either control group
    • Case group: 21.5%
    • Population control group: 9.3%
    • Cancer control group: 12.7%
    • Case vs population
      • OR 2.7 (95% CI, 1.4 to 5.1)
    • Case vs cancer controls
      • OR 1.9 (95% CI, 1.0 to 3.6)
  • However, there was no difference in odds of preterm birth <32 weeks among the groups
  • Neonatal morbidity was more common among the patients in the case group relative to those in the cervical cancer control group
    • Case group: 15.9%
    • Cancer control group: 6.9%
    • OR 2.5 (95% CI, 1.2 to 5.5)
  • There were no differences among the groups for rates of the following
    • Growth restriction | Stillbirth | Cesarean delivery | Maternal morbidity

CONCLUSION:

  • Patients with a history of stage 1 cervical cancer who conceived after fertility-sparing surgery experienced higher odds of preterm birth before 37 weeks
    • However, there was no difference in rates of preterm birth prior to 32 weeks
  • The authors state

This study provides evidence to foster shared decision-making discussions regarding obstetric outcomes after fertility-sparing treatment for early cervical cancer

With greater knowledge of these risks and close antenatal surveillance, there may be room for intervention to prolong gestation and achieve more favorable neonatal outcomes

Learn More – Primary Sources:

Outcomes of the First Pregnancy After Fertility-Sparing Surgery for Early-Stage Cervical Cancer

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Pregnant After Bariatric Surgery – a Risk Factor for Abdominal Surgery?
Treatment for Women with HIV and High-Grade Cervical Lesions: Cryotherapy or LEEP?
Which Factors Increase Risk for High-Grade CIN 2/3 Recurrence Following Treatment?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site